lydisilka
estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - dzimumhormoni un dzimumsistēmas modulatori dzimumorgānu sistēma, - mutes trakta kontracepcija. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - karcinoma, nesīkšūnu plaušas - antineoplastiski līdzekļi - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , triple kombinēto terapiju), kā palīglīdzekli, lai diētu un vingrošanu pacientiem nepietiekami kontrolē par to maksimālā pieļaujama devu metformīns un sulfonilurīnvielas pamata. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
paracetamol/codeine accord 500 mg/30 mg tabletes
accord healthcare b.v., netherlands - paracetamolum, codeini phosphas hemihydricus - tablete - 500 mg/30 mg
foscarnet sodium tillomed 24 mg/ml šķīdums infūzijām
tillomed pharma gmbh, germany - foscarnetum natricum hexahydricum - Šķīdums infūzijām - 24 mg/ml
procysbi
chiesi farmaceutici s.p.a - merkaptamīna bitartrāts - cistinoze - citas gremošanas trakta un metabolisma produkti, - procysbi ir indicēts apstiprinātas nefropātijas cistinozes ārstēšanai. cisteamīns samazina cistīna uzkrāšanos dažās šūnās (e. leikocīti, muskuļu un aknu šūnas) pacientiem ar nefropātiju cystinoze un, ja ārstēšana sākas agri, tas kavē nieru mazspēju.
raboral v-rg ēsma
boehringer ingelheim animal health france scs , francija - trakumsērgas vīrusa glikoproteīniem - ēsma - lapsas
dacepton 10 mg/ml šķīdums injekcijām/infūzijām
ever neuro pharma gmbh, austria - apomorfīna hidrohlorīda hemihidrāts - Šķīdums injekcijām/infūzijām - 10 mg/ml
lokren 20 mg apvalkotās tabletes
sanofi-aventis france, france - betaksolola hidrohlorīds - apvalkotās tabletes - 20 mg
dacepton 5 mg/ml šķīdums infūzijām
ever neuro pharma gmbh, austria - apomorfīna hidrohlorīda hemihidrāts - Šķīdums infūzijām - 5 mg/ml